For an abnormal mammogram or a palpable breast mass. ANDA 78806, held by Jubilant Draximage. Technetium Tc-99m Sestamibi Kit.
As of Nov 16, 2026, ANDA 78806 (Technetium Tc 99m Sestamibi), held by Jubilant Draximage, was first approved by FDA on Apr 29, 2009, with 1 approved supplement and 0 published complete response letters.
Myocardial Imaging: Kit for the preparation of Technetium Tc 99m Sestamibi Injection is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing information for use in patient management decisions. Technetium Tc 99m Sestamibi evaluation of myocardial ischemia can be accomplished with rest and cardiovascular stress techniques (e.g., exercise or pharmacologic stress in accordance with the pharmacologic stress agents labeling).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 29, 2009 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Technetium Tc 99m SestamibiN/A · injectable;injection | Technetium Tc-99m Sestamibi Kit | Rx |
| May 1, 2018 | Supplement 15Labeling · Standard review | Approved | None posted |
| Apr 29, 2009 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters